FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

스택 라이브러리

Anti-Anxiety Stack

Cognitive Enhancementbeginner

81

상호작용

81
Share
펩타이드

2

일 평균 mcg

700

수준

beginner

추가됨

May 17, 2026

개요

The Anti-Anxiety Stack pairs the anxiolytic peptide Selank with Delta Sleep-Inducing Peptide (DSIP) to address both daytime anxiety and the sleep disruption that typically accompanies chronic stress. Selank''s anxiolytic mechanism operates primarily through allosteric modulation of GABA-A receptors — similar to benzodiazepines but without binding to the benzodiazepine site itself. This produces anxiolysis without sedation, cognitive impairment, tolerance development, or physical dependence. Additionally, Selank stabilizes enkephalin levels in the blood (endogenous opioid peptides that modulate mood and pain), preventing the rapid enzymatic degradation that occurs under chronic stress conditions. DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide first isolated from rabbit cerebral venous blood during induced sleep. It modulates sleep architecture by promoting delta-wave (slow-wave) sleep — the deepest restorative phase that is typically disrupted by anxiety and chronic stress. DSIP also normalizes cortisol rhythms (reducing elevated evening cortisol that prevents sleep onset) and modulates GABA and serotonin systems. Clinical studies in humans have demonstrated improved sleep quality and reduced time to sleep onset without the hangover effects of pharmacological sleep aids. The combination addresses the anxiety-insomnia cycle from both ends: Selank during the day reduces the stress accumulation and rumination that disrupts evening wind-down, while DSIP at night restores restorative sleep that is essential for next-day stress resilience. Adequate deep sleep is required for emotional memory processing and HPA axis recovery — without it, anxiety compounds daily. This stack breaks that cycle through gentle, non-addictive peptide mechanisms that support rather than override natural neurotransmitter function. The beginner classification reflects the clean side-effect profiles of both compounds and their non-addictive nature.

용량 프로토콜

Selank

Twice per day· nasal

Selank에 대한 자세한 내용 →

300 mcg

1회 용량당

DSIP

nightly· subcutaneous

DSIP에 대한 자세한 내용 →

100 mcg

1회 용량당

목표 및 증거

Anxiety reductionStressCalmSleep onsetMood
증거 등급:인체 RCT

경고

  • Selank approved in Russia for anxiety. DSIP (Delta Sleep-Inducing Peptide) has limited but promising human data. Neither FDA-approved in US.

Comments

Sign in to join the discussion

주의: 이 스택은 커뮤니티에서 제출된 것이며 연구용으로만 사용됩니다. Peptide Contacts는 제출된 스택의 안전성이나 효능을 검증하지 않습니다. 펩타이드 프로토콜을 사용하기 전에 항상 자격이 있는 의료 전문가와 상의하세요.